Remission induction in very early rheumatoid arthritis: a comparison of etanercept plus methotrexate plus steroid with standard therapy

Trial Profile

Remission induction in very early rheumatoid arthritis: a comparison of etanercept plus methotrexate plus steroid with standard therapy

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate; Methylprednisolone acetate; Methylprednisolone acetate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RIVERA
  • Most Recent Events

    • 01 Dec 2015 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials.
    • 25 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 18 Jan 2011 Planned end date changed from 1 Oct 2009 to 30 May 2010 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top